Michel P Bihl
Overview
Explore the profile of Michel P Bihl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bihl M, Tornillo L, Kind A, Obermann E, Noppen C, Chaffard R, et al.
Appl Immunohistochem Mol Morphol
. 2015 Nov;
25(3):184-189.
PMID: 26580098
Accumulating evidence regarding the causative role of human papillomavirus (HPV) in a wide range of malignant and nonmalignant diseases highlights the importance of HPV testing. This study describes and discusses...
2.
3.
Hoeller S, Bihl M, Tzankov A, Chaffard R, Hirschmann P, Miny P, et al.
Hum Pathol
. 2014 Apr;
45(5):1003-9.
PMID: 24746204
Trisomy 21 alters fetal liver hematopoiesis and, in combination with somatic globin transcription factor 1 (GATA1) mutations, leads to development of transient myeloproliferative disease in newborns. However, little is known...
4.
Bihl M, Foerster A, Lugli A, Zlobec I
J Transl Med
. 2012 Aug;
10:173.
PMID: 22925370
Background: The aim of this study is to analyse CDKN2A methylation using pyrosequencing on a large cohort of colorectal cancers and corresponding non-neoplastic tissues. In a second step, the effect...
5.
Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A
Histopathology
. 2012 Jul;
61(5):777-87.
PMID: 22803799
Aims: In colorectal cancer, tumour budding, a process likened to epithelial mesenchymal transition, is an adverse prognostic factor which is rarely found in tumours with high-level microsatellite instability (MSI-H). Cases...
6.
Zlobec I, Bihl M, Foerster A, Rufle A, Terracciano L, Lugli A
Front Oncol
. 2012 Jun;
2:7.
PMID: 22655257
Background: The current proposed model of colorectal tumorigenesis is based primarily on CpG island methylator phenotype (CIMP), microsatellite instability (MSI), KRAS, BRAF, and methylation status of 0-6-Methylguanine DNA Methyltransferase (MGMT)...
7.
Bihl M, Hoeller S, Andreozzi M, Foerster A, Rufle A, Tornillo L, et al.
Diagn Mol Pathol
. 2012 Feb;
21(1):14-23.
PMID: 22306671
Targeting the epidermal growth factor receptor (EGFR) is a new therapeutic option for patients with metastatic colorectal or lung carcinoma. However, the therapy efficiency highly depends on the KRAS mutation...
8.
Sterlacci W, Tzankov A, Veits L, Zelger B, Bihl M, Foerster A, et al.
J Thorac Oncol
. 2011 Aug;
6(10):1649-57.
PMID: 21857254
Introduction: The role of p16 is gaining importance in non-small cell lung cancer (NSCLC) because of epigenetic therapy options. Further insight into the significance of protein expression, gene status and...
9.
Hoeller S, Bihl M, Zihler D, Cogliatti S, Ponzoni M, Zettl A, et al.
Hum Pathol
. 2011 Aug;
43(3):405-12.
PMID: 21855110
Aberrant expression of the antiapoptotic protein BCL (B-cell lymphoma)-2 in neoplastic germinal centers is one of the diagnostic hallmarks of follicular lymphoma. If BCL-2 cannot be detected by immunohistochemistry, the...
10.
Pilati C, Amessou M, Bihl M, Balabaud C, Tran Van Nhieu J, Paradis V, et al.
J Exp Med
. 2011 Jun;
208(7):1359-66.
PMID: 21690253
Inflammatory hepatocellular adenomas (IHCAs) are benign liver tumors. 60% of these tumors have IL-6 signal transducer (IL6ST; gp130) mutations that activate interleukin 6 (IL-6) signaling. Here, we report that 12%...